Fujifilm Diosynth Biotechnologies will manufacture the bulk substance for ThromboGenics’ FDA approved Jetrea (ocriplasmin) indicated for symptomatic vitreomacular adhesion (VMA).
The companies signed a long-term supply agreement in September 2010 and worked towards completing validation and setting up a well characterised procedure.
Fujifilm Diosynth Biotechnologies’ Billingham managing director Steve Bagshaw said, “This is fifth licensed biopharmaceutical manufactured by Fujifilm Diosynth Biotechnologies and the second made at our Billingham site, demonstrating our growing expertise in helping to transition biopharmaceuticals from the clinic to become marketed new drugs”.
Jetrea is an enzyme that breaks down proteins that lead to VMA in the eye. The protein breakdown results in enhanced separation between the vitreous and macula and minimizes the probability of tugging.
ThromboGenics CEO Dr. Patrik De Haes said, “Fujifilm Diosynth Biotechnologies has been a key partner in helping to bring our first drug to market. Their team at Billingham have done an excellent job in developing and validating a robust process and manufacturing material to enable us to launch the product on schedule.”
Â
